Clinical trials: Drug Withdrawal
Opioid Withdrawal, Opioid Use Disorder (OUD)
Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder
This study is evaluating the Sparrow Link, a wearable device that delivers gentle electrical signals to nerves in the outer ear (a technique known as transcutaneous auricular neurostimulation, or tAN).
- Trial name
- NCT07079826
- Testing
- Sparrow Link (Active tAN)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Payel Roy
Neonatal Opioid Withdrawal Syndrome
Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome.
Maternal use and addiction to opioids has resulted in an unprecedented rise in drug withdrawal complications in newborns known as neonatal opioid withdrawal syndrome (NOWS), also referred to as neonatal abstinence syndrome (NAS).
- Trial name
- NCT04834297
- Testing
- Prapela SVS mattress
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Tufts Medical Center
Rheumatoid Arthritis
Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
The purpose of this study is to assess the effect of disease-modifying anti-rheumatic drugs (DMARDs) dose reduction in patients with rheumatoid arthritis (RA).
- Trial name
- ARCTIC REWIND (NCT01881308)
- Testing
- TNF inhibitors, Synthetic DMARD(s), Co-medication: Synthetic DMARDs
- Where
- 10 sites in Norway
- Volunteers
- 320 people
- Sponsor
- Diakonhjemmet Hospital
Opiate Dependence, Drug Dependence
Treatment of Polydrug-Using Opiate Dependents During Withdrawal
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for…
- Conditions
- Opiate Dependence, Drug Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00367874
- Testing
- Buprenorphine, Valproate
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Sorlandet Hospital HF
Psoriatic Arthritis
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
- Trial name
- SPIRIT P3 (NCT02584855)
- Testing
- Ixekizumab
- Where
- 106 sites in United States, Bulgaria and 10 more
- Volunteers
- 394 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine, Medication Overuse Headache
Mindfulness Therapy for Chronic Migraine
The aim is to assess the efficacy of adding on a Mindfulness-based therapy to pharmacological prophylaxis (experimental group: pharmacological prophylaxis + Mindfulness) against pharmacological prophylaxis only (control group) on…
- Trial name
- Mind-CM (NCT03671681)
- Testing
- Mindfulness, Prophylactic
- Where
- Italy
- Volunteers
- 177 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
High Dosage Buprenorphine
High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid
The prevalence of analgesics opioids addiction in chronic pain patient is very difficult to know. Many studies indicated that the prevalence of addiction varied from 0% up to 50% in chronic non cancer pain patients, and from 0%…
- Trial name
- SEVROP (NCT03156907)
- Testing
- Buprenorphine
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Clermont-Ferrand
Alcohol Withdrawal Syndrome
Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome
The purpose of this study is to evaluate the efficacy and safety of levetiracetam for treating alcohol withdrawal syndrome (AWS) in inpatients (vs. placebo).
- Trial name
- NCT00146471
- Testing
- Levetiracetam
- Where
- 5 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Charite University, Berlin, Germany
Substance Withdrawal Syndrome
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Prescription opioid addiction is a growing public health problem and more pharmacologic treatments are needed because current approved medications have had limited patient acceptance (naltrexone), limited availability…
- Trial name
- NCT00980044
- Testing
- Tramadol
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Michelle Lofwall
Alcoholism
Evaluation of Physical Activity of Patients Admitted to Addiction Service
Addiction is a public health issue that affects nearly 30% of French people according to INSEE. For several years now, the investigators have known that sport is a real help in the fight against addictions, with recent medical…
- Trial name
- ACTP-ADDICT (NCT04953403)
- Where
- France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Montpellier
Intoxication, Delirium Tremens (DTs)
Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care
Background and purpose At present, occasional referral to psychiatric or addiction services is the only aftercare option offered following an intoxication/overdose requiring intensive care.
- Conditions
- Intoxication, Delirium Tremens (DTs), Poisoning by Psychoactive Substances, Suicidal Attempt
- Trial name
- NCT07819500
- Testing
- Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group
- Volunteers
- 50 people
- Sponsor
- Karolinska Institutet
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
The primary objective of this study is to assess lofexidine related effects on QTc (an interval of the heart rhythm) in subjects receiving buprenorphine maintenance.
- Trial name
- NCT01820442
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Alcohol Dependence, Alcohol Withdrawal Syndrome
Assessment of Valproate on Ethanol Withdrawal
Alcohol use disorder, or heavy drinking, is commonly seen in patients who present to trauma centers. These patients are at risk for Alcohol Withdrawal Syndrome (AWS), which is collection of symptoms that can range from anxiety…
- Conditions
- Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking
- Trial name
- PAVE (NCT03235531)
- Testing
- Valproate, Lorazepam
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- CAMC Health System
Hepatitis C, Hepatitis C, Chronic
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
In order to prevent organ rejection, patients receiving liver transplants currently require life-long treatment with immune system-suppressing medications to prevent the rejection of the transplanted liver.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
- Trial name
- A-WISH (NCT00135694)
- Testing
- calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids
- Where
- 8 sites in United States
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tobacco Dependence, Withdrawal Symptoms
Varenicline OTC Trial on Efficacy and Safety
The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
- Conditions
- Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
- Trial name
- VOTC (NCT03557294)
- Testing
- 1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d.
- Where
- 2 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Renal Transplant
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants.
- Trial name
- BESTT (NCT00346151)
- Testing
- Belatacept, Sirolimus, Anti-thymocyte globulin
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1).
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs-INO (NCT03911739)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 10 sites in United States
- Volunteers
- 71 people
- Sponsor
- T. John Winhusen, PhD
Baclofen Withdrawal Syndrome
Oral and IV Baclofen in Adult Volunteers
The primary objective of this study is to characterize baclofen pharmacokinetics following oral and intravenous administration in patients who are on chronic oral baclofen therapy.
- Trial name
- NCT01749319
- Testing
- Oral baclofen, Intervenous baclofen
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Opiate Addiction
Lofexidine for Inpatient Opiate Detox
The main objective of this study is to investigate the effectiveness of lofexidine in reducing withdrawal symptoms among subjects undergoing opiate detoxification.
- Trial name
- NCT00235729
- Testing
- Lofexidine
- Where
- 16 sites in United States
- Volunteers
- 264 people
- Sponsor
- US Department of Veterans Affairs
Drug Withdrawal Symptoms, Critical Care
Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment
The study is a prospective interventional study with three main aims: 1. Describe the frequency and severity of withdrawal syndrome in a population of paediatric intensive care patients. 2.
- Conditions
- Drug Withdrawal Symptoms, Critical Care, Child
- Trial name
- ASWISPIC (NCT02952846)
- Testing
- Algorithm for tapering og analgosedation
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital